索拉非尼联合加味逍遥散治疗原发性肝癌的效果观察

Effect of sorafenib combined with xiaoyao Powder in the treatment of primary liver cancer

目的:研究用索拉非尼联合加味逍遥散治疗原发性肝癌的效果。方法:选取2019年1月至2020年12月广州市番禺区中医院收治的62例原发性肝癌患者作为研究对象。将其随机分为研究组和对照组。对照组患者口服索拉非尼进行治疗,研究组患者口服索拉非尼联合加味逍遥散进行治疗。比较两组患者的临床疗效及不良反应的发生率。结果:研究组患者治疗的总有效率(RR)和疾病的控制率(DCR)均略高于对照组患者,P>0.05。用药后,两组患者不良反应的发生率相比,P>0.05。结论:与单用索拉非尼治疗原发性肝癌相比,用索拉非尼联合加味逍遥散治疗此病可在一定程度上提高患者的疗效,且用药的安全性较高。

Objective:To study the effect of sorafenib combined with xiaoyao Powder in the treatment of primary liver cancer.Methods:A total of 62 patients with primary liver cancer admitted to Panyu Hospital of Traditional Chinese Medicine in Guangzhou from January 2019 to December 2020 were selected as the study subjects.They were randomly divided into study group and control group.Control group was treated with oral sorafenib,and study group was treated with oral sorafenib combined with flavored Xiaoyao Powder.The clinical efficacy and incidence of adverse reactions were compared between the two groups.Results:The total effective rate(RR)and disease control rate(DCR)in the study group were slightly higher than those in the control group,P>0.05.After medication,the incidence of adverse reactions in 2 groups was compared,P>0.05.Conclusion:Compared with sorafenib alone in the treatment of primary liver cancer,sorafenib combined with flavored Xiaoyao Powder in the treatment of this disease can improve the efficacy of patients to a certain extent,and the safety of medication is higher.